Clinical trial
Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B…
NCT00411697 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00411697 |
|---|---|
| Title | Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B Vaccine Challenge |
| Official title | Assess Long-term Persistence of Hepatitis B Antibodies & Immune Response to a Hepatitis B Vaccine (Engerix-B Kinder) Challenge in Children Aged 4-5 Years (Previously Primed & Boosted in the 1st 2 Years of Life With DTPa-HBV-IPV/Hib Vaccine) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | Engerix™-B Kinder |
| Enrollment | 301 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Dec 14, 2006 |
| Last update posted | Oct 28, 2016 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: